Please ensure Javascript is enabled for purposes of website accessibility

3 New Drug Launches of 2020 -- and the Stocks That Could Win Big

By Cory Renauer - Aug 17, 2020 at 8:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sales of these recently launched products could make a big difference for the companies behind them.

Social distancing measures aimed at controlling the coronavirus pandemic have slowed down a lot of government agencies, but they haven't prevented regulators from reviewing new drug applications at a rapid pace. The FDA has already approved 35 novel new drugs this year, and keeping up with all of them is a task few of us have time for.

Recently, Evaluate, a healthcare analytics service, ranked recently approved drugs according to consensus sales forecasts from industry analysts. Here's what investors should know about new products that rose to the top from Immunomedics (IMMU), Esperion (ESPR 3.59%), and Bristol Myers Squibb (BMY -0.53%).

Three pill bottles with cash money in them.

Image source: Getty Images.

1. Trodelvy from Immunomedics

In April the FDA approved Trodelvy, a new treatment option for patients with triple-negative breast cancer (TBNC), a form of the disease that doesn't respond to the most commonly used targeted therapies. Trodelvy's an antibody linked to a chemotherapy bomb that it doesn't drop until recognizing Trop-2, a protein commonly found on the surface of TNBC tumor cells.

Out of 108 patients treated in a pivotal trial leading to its approval, Trodelvy shrank tumors for 36 patients, three of which achieved complete remission. If you're not an oncologist, this 33.3% response rate might not seem like anything to write home about. It's important to understand that each time a line of treatment fails a cancer patient, their prognosis worsens and a majority of these patients had already progressed after three or more lines of therapy before attempting Trodelvy.

Trodelvy's target frequently appears on tumor cells that originate in other organs, including the pancreas. As a treatment for the underserved TNBC population now and additional populations in the years ahead, sales of the drug are expected to reach $2.3 billion by 2026.

2. Nexletol from Esperion

In March, biotech company Esperion launched its first product, Nexletol, a cholesterol-lowering drug formerly known as bempedoic acid for patients with hereditary hypercholesterolemia and heart problems caused by clogged arteries. This enormous group of patients can usually keep their cholesterol levels in check with cheap generic statins, but there are millions who need something more powerful.

More recently, the company earned approval to market Nexlizet for the same group of patients. This is a combination of bempedoic acid and Zetia, an older drug that limits the amount of cholesterol absorbed from each meal. 

As a treatment for millions of people worldwide who can't get their cholesterol under control with statins, annual Nexletol franchise sales are expected to reach $1.8 billion in 2026. Before getting too excited about Esperion, it's important to realize that the market for expensive new non-statin cholesterol treatments is already crowded by injectable drugs such as Praluent and Repatha.

Nexletol's in a long-term outcome study right now that won't read out until 2022. If the results don't make a strong case for Nexletol versus injectable treatments, Esperion could have a tough time meeting any sales expectations.

3. Zeposia from Bristol Myers Squibb

Zeposia is a once-daily capsule for patients with relapsing multiple sclerosis that Bristol Myers Squibb acquired from Celgene. The coronavirus pandemic hasn't helped Bristol Myers Squibb launch Zeposia following its approval this March. During the second quarter, sales reached just $1 million.

Long-term sales forecasts for Zeposia have fallen since the FDA refused to file the first application Celgene submitted in 2018. Despite the delay, annual Zeposia sales are expected to reach $1.6 billion by 2026.

Over the past few years, competition for a limited pool of multiple sclerosis patients has risen sharply. In 2017, the FDA approved a twice-annual infusion from Roche (RHHBY -2.50%) called Ocrevus, and sales of this competing MS drug already reached $2.3 billion during the first half of 2020.

Most likely to beat the market?

Meeting consensus sales estimates would help these stocks rise, but Bristol Myers Squibb is already a pharmaceutical behemoth. That means a successful Zeposia launch on its own won't move the entire needle very far.

Esperion's attempt to carve out a niche for Nexletol could turn out to be an uphill struggle the company isn't prepared for. Immunomedics' Trodelvy launch, on the other hand, is moving along at an encouraging pace with $20 million in net sales during the first two months following its launch. If there's a stock here worth investigating further, it's Immunomedics.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Immunomedics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$74.46 (-0.53%) $0.40
Immunomedics, Inc. Stock Quote
Immunomedics, Inc.
Esperion Therapeutics Stock Quote
Esperion Therapeutics
$6.64 (3.59%) $0.23
Roche Holding AG Stock Quote
Roche Holding AG
$41.04 (-2.50%) $-1.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.